Suggestions
Susan Galbraith
Executive Vice President Oncology R&D at AstraZeneca
Dr. Susan Galbraith is a UK trained Clinical Oncologist with a strong background in Oncology early drug development and Biomarker development.
She holds a PhD in Oncology focusing on Vascular Targeting Agents, particularly on endothelial cell shape change effects, and has utilized translational dynamic MRI to measure effects on tumor microcirculation.
Dr. Galbraith is a Fellow of the Academy of Medical Sciences (FMedSci) and has a comprehensive educational background, having studied MB BChir in Clinical Medicine at the University of Cambridge and BSc in Physiology at The University of Manchester.
With vast experience in the pharmaceutical industry, she has held key leadership positions at AstraZeneca, including Executive Vice President and Former Senior Vice President of Early Oncology, as well as Former Senior Vice President IMED Oncology.
Prior to her tenure at AstraZeneca, Dr. Galbraith served as Vice-President of Oncology Discovery Medicine and Clinical Biomarkers at Bristol-Myers Squibb in Princeton, New Jersey.
Highlights
On the heels of an action-packed #WCLC24 in San Diego, I’m delighted to be in Barcelona for #ESMO24 where we have more than 80 abstracts that collectively demonstrate our aim to redefine cancer care across different tumours and stages of disease. I’m particularly proud that once again we’re part of the Presidential Symposia, which showcase cutting-edge and significant clinical practice-changing studies. My thanks to AstraZeneca colleagues and our external partners for all you do to transform outcomes – I look forward to seeing many of you over the weekend.
Summer is here and the warmer weather and longer days are a good opportunity to catch up on the scientific literature. A recent paper published in the journal Science got me thinking about cell membranes and how little we know about what’s happening on them. Better understanding protein interactions on and between cell surfaces could unlock some of the mysteries of cellular communication and help us discover new therapeutic targets.
The cell membrane is a hub of activity, with proteins constantly interacting to mediate cellular activity. These interactions are challenging to capture, as many, such as those involved in signal transduction, are transient. Proximity labelling proteomics (PLP) approaches have allowed researchers to begin mapping “protein neighborhoods” by using localized catalysis to irreversibly mark proteins that interact with a target protein. So far, PLP approaches have been limited by the need for complex protein engineering and the need to switch between different probe-catalyst combinations to examine interactions at differing resolutions; there hasn’t yet been a streamlined approach for examining protein neighborhoods whether on crowded cell surfaces or between interacting cells.
Now, a new photocatalytic proximity labelling approach, named MultiMap, has been reported. Based on a well-understood and commercially available photocatalyst, Eosin-Y (EY), MultiMap can use different photo-probes to capture protein interactions at varying resolutions, from high resolution nearest-neighbour analyses to lower resolution intercellular interactions. It uses one simplified workflow that does not require complex protein engineering. Researchers can easily conjugate EY to an antibody, facilitating the capture of interactions for their protein of interest.
The researchers demonstrated the use of MultiMap by mapping the neighborhood of the epidermal growth factor receptor (EGFR). They identified and validated more than 20 known and new EGFR neighbors, including some that were known to be functionally associated but for which no structural evidence for interaction had been previously reported. Interestingly, the researchers note that it is unlikely that all the identified neighbours interact with EGFR at the same time, suggesting that EGFR can be found in different neighborhoods that have different functions. It’ll be interesting to see how our understanding of cell membrane dynamics and function evolve with this insight.
I think that MultiMap has the potential to drive some interesting new research directions. For example, it could help us more deeply interrogate and understand the tumour microenvironment so that we can better understand protein interactions that influence therapeutic outcomes. Also, it is possible that enhanced understanding of protein neighborhoods could help suggest and fine-tune novel context-dependent targeted therapies.
